Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

NCT00109161 is registered in ClinicalTrials.gov with PDL BioPharma, Inc. as lead sponsor.

NCT NCT00109161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00109161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
Lead sponsor
PDL BioPharma, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2005
Completion date
October 31, 2006
Enrollment
270
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis